1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

US Companion Diagnostics Market Trends and Insights

  • April 2014
  • 121 pages
  • Frost & Sullivan
Report ID: 2114650

Summary

Table of Contents

A complete companion diagnostic market analysis must include both developers of targeted drugs and developers of companion diagnostic tests. This research deliverable discusses important trends in the U.S. companion diagnostics market including emerging opportunities with novel drug classes and new clinical markers like circulating tumor cells. Emerging therapeutic areas beyond oncology for companion diagnostics are also discussed along with key competitors, rx-cdx partnerships, regulatory overview, and therapeutic pipelines with companion biomarkers.


Key Findings

There were at least 387 targeted medicines in the pipeline or currently marketed for oncology in 2013. breast cancer, non-small cell lung cancer (NSCLC), and colorectal cancer have the most targeted drug development activity.

Novartis and Roche lead with the most targeted therapies currently marketed and in development. AstraZeneca, GSK, Pfizer, Sanofi, and BMS are also focused on targeted therapies marketed with or likely requiring a companion diagnostics (CDx).

Key market drivers include the unmet need for Cdx in highly mutationally driven cancers such as NSCLC and melanoma and the growing interest in novel clinical epigenetic biomarkers and circulating tumor cells.

A promising new drug class, the antibody drug conjugate (ADC), may provide new opportunities for CDx. Roche, ImmunoGen, and Seattle Genetics all have a high number of ADCs in the pipeline and may be attractive targets for CDx partnering.

Advances such as highly sensitive microfluidic biosensors, single cell analysis, and deep sequencing of circulating cell-free tumor DNA are making the concept of the liquid biopsy, or the ability to monitor a tumor noninvasively, a near-term reality.

Oncology is the primary therapeutic area for CDx development, but neurological, cardiovascular, gastrointestinal, and muscular diseases are growing areas for CDx. Within oncology, lung cancer was the most prominent area where most partnerships between manufacturers were observed.

Most CDx partnerships were defined over the regions of the United States and Europe, the two most important CDx markets.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending ...

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

“Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics ...

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK - Forecast

  • June 2017
    38 pages
  • Cancer  

  • United Kingdom  

View report >

Global Mortality Industry

  • June 2017
    4 pages
  • Mortality  

    Cancer  

    Dementia  

  • United States  

    World  

View report >

Obesity Statistics in the US

  • June 2017
    10 pages
  • Obesity  

    Cytokine  

  • United States  

View report >

Related Market Segments :

Lung Cancer
Biomarker

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.